Amador M et al. Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer: a retrospective analysis. Am J Clin Oncol 2004; (3):269-73. Abstract

Atkins CD. Dose-dense chemotherapy as adjuvant treatment for breast cancer. J Clin Oncol 2004;22(4):749-50. Abstract

Bonadonna G et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. J Clin Oncol 2004;22(9):1614-20. Abstract

Budd GT et al. Long-term followup of SWOG 8313: CMFVP vs FAC-M as adjuvant therapy of node-positive, ER-negative breast cancer. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 132.

Citron ML et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Earl H, Iddawela M. Epirubicin as adjuvant therapy in breast cancer. Expert Rev Anticancer Ther 2004(2):189-95. Abstract

Ellis GK et al. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002;20(17):3637-43. Abstract

Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004;10(10):3249- 61. Abstract

Fountzilas G et al. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer. Oncology 2001;60(3):214-20. Abstract

Fumoleau P et al. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol 2001;19:612-20. Abstract

Fumoleau P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003;21:298-305. Abstract

Goldhirsch A et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65. Abstract

Gradishar WJ. Adjuvant systemic therapy of early stage breast cancer. Curr Treat Options Oncol 2003;4(2):141-50. Abstract

Hery M et al. Disease-free survival improvement with an epirubicin-based chemotherapy in poor prognosis, node-negative breast cancer patients: 10-year follow-up results of French Adjuvant Study Group 03 trial. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 140.

Jackisch C et al. Dose-dense biweekly doxorubicin/ docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/ docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 2002;3(4):276- 80. Abstract

Leonard JP. Improved outcomes from dosedense adjuvant chemotherapy for breast cancer with growth factor support. Curr Hematol Rep 2003;2(6):451-2.No abstract available.

Love N, Hudis C. Adjuvant chemotherapy for early breast cancer: protocol and nonprotocol treatment options. Oncology (Huntingt) 2004;18(4 Suppl 1):5-22. No abstract available.

Mamounas EP et al. Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer. Clin Breast Cancer 2004;4(Suppl 3):121-6. Abstract

Martin M, On behalf of the BCIRG 001 Investigators. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 43.

Martin M et al. Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: first safety analysis of GEICAM 9906 trial. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 136.

Miles DW et al. Comparison of three weekly (q3w) vs four weekly (q4w) adjuvant CMF chemotherapy in operable breast cancer. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 135.

Mitchell Pl et al. A phase II study of escalateddose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Ann Oncol 2004;15(4):585-9. Abstract

O’Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003;4(5):318-28. Abstract

Petit T et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004;40(2):205-11. Abstract

Piccart MJ et al. New data on chemotherapy in the adjuvant setting. Breast 2003;12(6):373-8. Abstract

Roche H et al. Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel (Taxotere) for node positive breast cancer. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 144.

Smith IE et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004;15(5):751-8. Abstract

Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 2003 Dec;30(6):730-9. Abstract

Valero V et al. Long-term results of patients with breast cancer with 10 or more positive axillary lymph node treated with adjuvant anthracyclinecontaining therapy. The University of Texas M.D. Anderson Cancer Center (MDACC) experience. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 139.

Venturini M et al. Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO MIG1 study. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 12.

Zander AR et al. High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial. J Clin Oncol 2004 Apr 26 [Epub ahead of print] Abstract